✦ LIBER ✦

Independence of cocaine sensitization and amygdaloid kindling in the rat

✍ Scribed by A. Rackham; R.A. Wise

Book ID: 118350402
Publisher: Elsevier Science
Year: 1979
Tongue: English
Weight: 294 KB
Volume: 22
Category: Article
ISSN: 0031-9384
DOI: 10.1016/0031-9384(79)90221-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Kindling: The Amygdaloid Kindling in Dev

Kindling: The Amygdaloid Kindling in Developing, Adult and Aged Rats

✍ Shigeru Chiba; Yukihiro Muneoka; Shunsuke Kamata; Hiroko Inaba; Yuzuru Sato; Tsu 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Modification of dopaminergic receptor se

Modification of dopaminergic receptor sensitivity in rat brain after amygdaloid kindling

✍ Kelvin W. Gee; Mannfred A. Hollinger; John F. Bowyer; Eva K. Killam 📂 Article 📅 1979 🏛 Elsevier Science 🌐 English ⚖ 451 KB

Cocaine and “pharmacological kindling” i

Cocaine and “pharmacological kindling” in the rat

✍ Jeffrey S. Stripling 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 340 KB

Effect of dipotassium clorazepate on amy

Effect of dipotassium clorazepate on amygdaloid-kindling and comparison between amygdaloid- and hippocampal-kindled seizures in rats

✍ Kouichiro Amano; Junichi Takamatsu; Akira Ogata; Shouichi Katsuragi; Chihiro Miy 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Effect of amygdaloid kindling on dopamin

Effect of amygdaloid kindling on dopamine-sensitive adenylate cyclase activity in rat brain

✍ Kelvin W. Gee; Eva K. Killam; Mannfred A. Hollinger; Shri N. Giri 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 494 KB

Effects of kynurenic acid on amygdaloid

Effects of kynurenic acid on amygdaloid kindling in the rat

✍ James L Thompson; Gregory L Holmes; Gregory W Taylor; Daniel R Feldman 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 756 KB

The anticonvulsant properties of the endogenous excitatory amino acid antagonist, kynurenic acid (KYA), were studied in prepubescent and adult rats using the amygdaloid kindling model of epilepsy. Treatment with intracerebroventricular KYA (360 nmoles (adult dose) or 240 nmoles (prepuhescent dose))